Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.
Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.
J Mol Cell Cardiol. 2020 May;142:14-23. doi: 10.1016/j.yjmcc.2020.03.015. Epub 2020 Apr 2.
There is currently a growing global burden of valvular heart diseases due to aging populations and changing lifestyles. Valvular heart diseases mainly include the malfunctioning of aortic and mitral valves and are characterized by extensive tissue remodeling, which includes calcification, endothelial dysfunction, and endothelial-mesenchymal transition. These valvular remodeling processes are known to be regulated by protein-coding genes as well as non-coding genes. Here, we have summarized studies highlighting the non-coding RNA mediated regulation of valvular tissue remodeling and their potential therapeutic benefits. Additionally, studies investigating the diagnostic capability of circulating non-coding RNA molecules in valvular diseases are also summarized. Overall, of the various candidates, several studies have highlighted miR-214 and miR-204 as central regulators of valvular calcification.
目前,由于人口老龄化和生活方式的改变,全球范围内瓣膜性心脏病的负担日益加重。瓣膜性心脏病主要包括主动脉瓣和二尖瓣的功能障碍,其特征是广泛的组织重塑,包括钙化、内皮功能障碍和内皮-间充质转化。这些瓣膜重塑过程被认为受蛋白编码基因和非编码基因的调节。在这里,我们总结了强调非编码 RNA 介导的瓣膜组织重塑及其潜在治疗益处的研究。此外,还总结了研究循环非编码 RNA 分子在瓣膜疾病中的诊断能力的研究。总的来说,在各种候选物中,有几项研究强调了 miR-214 和 miR-204 是瓣膜钙化的核心调节剂。